MAP1LC3B2

gene
On this page

Also known as ATG8G

Summary

MAP1LC3B2 (microtubule associated protein 1 light chain 3 beta 2, HGNC:34390) is a protein-coding gene on chromosome 12q24.22, encoding Microtubule-associated protein 1 light chain 3 beta 2 (A6NCE7). Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes).

Predicted to enable microtubule binding activity; phosphatidylethanolamine binding activity; and ubiquitin protein ligase binding activity. Predicted to be involved in cellular response to nitrogen starvation and macroautophagy. Predicted to be located in several cellular components, including cytoplasmic vesicle; endomembrane system; and microtubule. Predicted to be active in autophagosome membrane.

Source: NCBI Gene 643246 — RefSeq curated summary.

At a glance

  • Gene–disease (curated): hereditary predisposition to infections (Limited, GenCC)
  • GWAS associations: 2
  • Clinical variants (ClinVar): 22 total
  • MANE Select transcript: NM_001085481

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:34390
Approved symbolMAP1LC3B2
Namemicrotubule associated protein 1 light chain 3 beta 2
Location12q24.22
Locus typegene with protein product
StatusApproved
AliasesATG8G
Ensembl geneENSG00000258102
Ensembl biotypeprotein_coding
OMIM620673
Entrez643246

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding_CDS_not_defined, 1 protein_coding, 1 retained_intron

ENST00000547114, ENST00000556529, ENST00000625301, ENST00000630062

RefSeq mRNA: 1 — MANE Select: NM_001085481 NM_001085481

CCDS: CCDS41841

Canonical transcript exons

ENST00000556529 — 2 exons

ExonStartEnd
ENSE00002522833116575842116576606
ENSE00003771783116559381116559433

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 87.93.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4365 / max 163.3760, expressed in 76 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter IDTPM avgSamples expressed
1282300.142731
1282310.091820
1282370.078831
2069160.063715
1282290.059517

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
cerebellar hemisphereUBERON:000224587.93gold quality
cerebellar cortexUBERON:000212987.82gold quality
cerebellumUBERON:000203787.76gold quality
right hemisphere of cerebellumUBERON:001489087.71gold quality
bloodUBERON:000017885.85gold quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047383.40gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099182.39gold quality
left ovaryUBERON:000211981.02gold quality
gastrocnemiusUBERON:000138880.69gold quality
tibial nerveUBERON:000132380.64gold quality
prefrontal cortexUBERON:000045180.54gold quality
stromal cell of endometriumCL:000225579.53gold quality
ovaryUBERON:000099279.32gold quality
right ovaryUBERON:000211879.20gold quality
muscle of legUBERON:000138378.68gold quality
sural nerveUBERON:001548878.59gold quality
cortical plateUBERON:000534378.42gold quality
skin of abdomenUBERON:000141677.81gold quality
frontal cortexUBERON:000187077.70gold quality
hindlimb stylopod muscleUBERON:000425277.43gold quality
zone of skinUBERON:000001477.01gold quality
primary visual cortexUBERON:000243676.91gold quality
skin of legUBERON:000151176.70gold quality
omental fat padUBERON:001041476.64gold quality
superior frontal gyrusUBERON:000266176.59gold quality
granulocyteCL:000009475.98gold quality
mucosa of stomachUBERON:000119975.91gold quality
brainUBERON:000095575.89gold quality
left uterine tubeUBERON:000130375.78gold quality
heart left ventricleUBERON:000208475.77gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3yes16.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting MAP1LC3B2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-5692A100.0074.406850
HSA-MIR-428299.9975.366408
HSA-MIR-6508-5P99.9270.672465
HSA-MIR-211-5P99.7971.652440
HSA-MIR-204-5P99.7971.622439
HSA-MIR-320A-3P99.7769.732107
HSA-MIR-320B99.7769.732107
HSA-MIR-320C99.7769.732107
HSA-MIR-320D99.7769.732107
HSA-MIR-442999.7769.622111
HSA-MIR-467999.7669.191229
HSA-MIR-518A-5P99.7069.012209
HSA-MIR-52799.7069.012209
HSA-MIR-452-5P99.6569.631762
HSA-MIR-4676-3P99.6569.311733
HSA-MIR-892C-3P99.6569.381745
HSA-MIR-432899.5771.064094
HSA-MIR-6832-3P99.5270.441726
HSA-MIR-629-5P98.7868.721032
HSA-MIR-5197-3P98.7167.051905
HSA-MIR-432-5P98.0068.13989
HSA-MIR-188-5P97.8967.01756
HSA-MIR-203B-3P97.8266.27979
HSA-MIR-483-3P97.7764.95731
HSA-MIR-4708-5P97.7767.82831
HSA-MIR-6866-3P97.3866.94748
HSA-MIR-6874-5P95.7364.94545

Cross-species orthologs

2 orthologs

OrganismSymbolGene ID
danio_reriomap1lc3bENSDARG00000101127
caenorhabditis_elegansWBGENE00002981

Paralogs (6): GABARAPL2 (ENSG00000034713), MAP1LC3A (ENSG00000101460), GABARAPL1 (ENSG00000139112), MAP1LC3B (ENSG00000140941), GABARAP (ENSG00000170296), MAP1LC3C (ENSG00000197769)

Protein

Protein identifiers

Microtubule-associated protein 1 light chain 3 beta 2A6NCE7 (reviewed: A6NCE7)

Alternative names: Microtubule-associated proteins 1A/1B light chain 3 beta 2, Microtubule-associated proteins 1A/1B light chain 3B-like

All UniProt accessions (1): A6NCE7

UniProt curated annotations — full annotation on UniProt →

Function. Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes). Plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. In response to cellular stress and upon mitochondria fission, binds C-18 ceramides and anchors autophagolysosomes to outer mitochondrial membranes to eliminate damaged mitochondria. While LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation.

Subunit / interactions. 3 different light chains, LC1 (a cleavage product of MAP1B), LC2 (a cleavage product of MAP1A) and LC3 (produced by one of the MAP1LC3 genes), can associate with the MAP1A or MAP1B heavy chains.

Subcellular location. Cytoplasmic vesicle. Autophagosome membrane. Endomembrane system. Cytoplasm. Cytoskeleton.

Post-translational modifications. The precursor molecule is cleaved by ATG4 (ATG4A, ATG4B, ATG4C or ATG4D) to expose the glycine at the C-terminus and form the cytosolic form, LC3-I. The processed form is then activated by APG7L/ATG7, transferred to ATG3 and conjugated to phosphatidylethanolamine (PE) phospholipid to form the membrane-bound form, LC3-II. During non-canonical autophagy, the processed form is conjugated to phosphatidylserine (PS) phospholipid. ATG4 proteins also mediate the delipidation of PE-conjugated forms. In addition, ATG4B and ATG4D mediate delipidation of ATG8 proteins conjugated to PS during non-canonical autophagy.

Similarity. Belongs to the ATG8 family.

RefSeq proteins (1): NP_001078950* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR004241Atg8-likeFamily
IPR029071Ubiquitin-like_domsfHomologous_superfamily

Pfam: PF02991

UniProt features (5 total): lipid moiety-binding region 2, chain 1, propeptide 1, site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-A6NCE7-F192.120.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 120–121 (cleavage; by atg4b)

Post-translational modifications (2): 120, 120

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 62 (showing top): GOBP_VACUOLE_ORGANIZATION, GOCC_VACUOLAR_MEMBRANE, GOBP_MACROAUTOPHAGY, GOBP_ORGANELLE_ASSEMBLY, GOBP_CELLULAR_RESPONSE_TO_STARVATION, GOBP_AUTOPHAGOSOME_ORGANIZATION, GOBP_RESPONSE_TO_STARVATION, SASSON_RESPONSE_TO_GONADOTROPHINS_UP, GOCC_AUTOPHAGOSOME, GOCC_AUTOPHAGOSOME_MEMBRANE, chr12q24, GOMF_CYTOSKELETAL_PROTEIN_BINDING, GOMF_UBIQUITIN_LIKE_PROTEIN_LIGASE_BINDING, GOMF_LIPID_BINDING, GOMF_PHOSPHOLIPID_BINDING

GO Biological Process (6): autophagosome assembly (GO:0000045), mitophagy (GO:0000423), cellular response to nitrogen starvation (GO:0006995), autophagosome maturation (GO:0097352), autophagy of mitochondrion (GO:0000422), autophagy (GO:0006914)

GO Molecular Function (4): microtubule binding (GO:0008017), phosphatidylethanolamine binding (GO:0008429), ubiquitin protein ligase binding (GO:0031625), phospholipid binding (GO:0005543)

GO Cellular Component (8): autophagosome membrane (GO:0000421), microtubule (GO:0005874), endomembrane system (GO:0012505), cytoplasmic vesicle (GO:0031410), cytoplasm (GO:0005737), autophagosome (GO:0005776), cytoskeleton (GO:0005856), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure3
macroautophagy2
vacuole2
Atg12 activating enzyme activity1
protein-phosphatidylethanolamide deconjugating activity1
Atg12 conjugating enzyme activity1
Atg12 ligase activity1
organelle assembly1
Atg1/ULK1 kinase complex assembly1
autophagosome organization1
autophagy of mitochondrion1
cellular response to starvation1
cellular response to nitrogen levels1
protein-containing complex disassembly1
autophagy1
catabolic process1
transmembrane transport1
process utilizing autophagic mechanism1
tubulin binding1
phospholipid binding1
ubiquitin-like protein ligase binding1
lipid binding1
vacuolar membrane1
autophagosome1
microtubule cytoskeleton1
polymeric cytoskeletal fiber1
plasma membrane1
cytoplasm1
intracellular vesicle1
intracellular anatomical structure1
intracellular membraneless organelle1

Protein interactions and networks

STRING

1085 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
MAP1LC3B2SQSTM1Q13501644
MAP1LC3B2ATG5Q9H1Y0611
MAP1LC3B2ATG3Q9NT62591
MAP1LC3B2ATG12O94817577
MAP1LC3B2ATG7O95352541
MAP1LC3B2NBR1Q14596529
MAP1LC3B2ATG4AQ8WYN0487
MAP1LC3B2CALCOCO2Q13137487
MAP1LC3B2BECN1Q14457479
MAP1LC3B2ATG16L1Q676U5452
MAP1LC3B2ATG9AQ7Z3C6450
MAP1LC3B2ATG10Q9H0Y0439
MAP1LC3B2ATG13O75143438
MAP1LC3B2DIMT1Q9UNQ2433
MAP1LC3B2BNIP3LO60238427

IntAct

23 interactions, top by confidence:

ABTypeScore
TSPAN3MAP1LC3B2psi-mi:“MI:0914”(association)0.530
SLC9A6MAP1LC3B2psi-mi:“MI:0914”(association)0.530
ATG3MAP1LC3B2psi-mi:“MI:0914”(association)0.530
TNFRSF10AMAP1LC3B2psi-mi:“MI:0914”(association)0.350
RUSF1MAP1LC3B2psi-mi:“MI:0914”(association)0.350
RETREG1MAP1LC3B2psi-mi:“MI:0914”(association)0.350
ATG3MAP1LC3B2psi-mi:“MI:0914”(association)0.350
NUFIP1MAP1LC3B2psi-mi:“MI:0914”(association)0.350
KIF3AMAP1LC3B2psi-mi:“MI:0914”(association)0.350
MAP1LC3BMAP1LC3B2psi-mi:“MI:0914”(association)0.350
ATG10MAP1LC3B2psi-mi:“MI:0914”(association)0.350
Npc1ESYT2psi-mi:“MI:0914”(association)0.350
CAV1MAP1LC3B2psi-mi:“MI:0914”(association)0.350
SNX33MAP1LC3B2psi-mi:“MI:0914”(association)0.350
TPX2MAP1LC3B2psi-mi:“MI:0914”(association)0.350
ATG4BMAP1LC3B2psi-mi:“MI:0914”(association)0.350

BioGRID (26): MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-Western), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS), MAP1LC3B2 (Affinity Capture-MS)

ESM2 similar proteins: A1CQS1, A1D3N4, A2XXR7, A2YAG8, A2YS06, A6NCE7, A6RPU4, A7KAL9, I1S1W5, J4UTT5, M1C146, M2SQA5, N4X184, O41515, P0CM28, P0CM29, P60519, P60520, P60521, P60522, Q0C804, Q0V3Y9, Q1E4K5, Q1SF86, Q2HJ23, Q2RBS4, Q2UBH5, Q2XPP5, Q4P2U6, Q4WJ27, Q69NP0, Q69RC4, Q6XVN8, Q6Z1D5, Q7XPR1, Q86CR8, Q8J282, Q8LEM4, Q8S924, Q8S925

Diamond homologs: A0A1B7XV12, A1CQS1, A1D3N4, A2QPN1, A2XXR7, A2YS06, A3GFU8, A4LA70, A5DWI6, A6NCE7, A6RPU4, A6ZKM4, A7E8H4, A7KAL9, A7TDU7, C4B4E4, I1S1W5, J4UTT5, M1C146, M2SQA5, N4X184, O41515, O94272, O95166, P0C075, P0CO54, P0CO55, P38182, P60517, P60518, P60519, P60520, P60521, P60522, P87068, Q09490, Q0C804, Q0V3Y9, Q0VGK0, Q1E4K5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 16 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO termPartnersFoldFDR
protein transport516.9×4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

22 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance18
Likely benign0
Benign3

Top pathogenic / likely-pathogenic (0)

SpliceAI

312 predictions. Top by Δscore:

VariantEffectΔscore
12:116575834:A:AGacceptor_gain0.9900
12:116575835:A:Gacceptor_gain0.9900
12:116575840:A:AGacceptor_gain0.9900
12:116575841:G:GGacceptor_gain0.9900
12:116575841:GCCTT:Gacceptor_gain0.9900
12:116575831:T:TAacceptor_gain0.9800
12:116575841:GC:Gacceptor_gain0.9800
12:116575841:GCC:Gacceptor_gain0.9800
12:116575838:ATAGC:Aacceptor_loss0.9700
12:116575840:A:ATacceptor_loss0.9700
12:116575828:T:Gacceptor_loss0.9600
12:116575841:GCCT:Gacceptor_gain0.9600
12:116560178:C:Gdonor_gain0.9300
12:116559430:GCGG:Gdonor_gain0.8800
12:116559768:TCC:Tdonor_gain0.8800
12:116560177:GC:Gdonor_gain0.8800
12:116575837:A:Gacceptor_gain0.8800
12:116560178:C:CGdonor_gain0.8700
12:116559531:C:Tdonor_gain0.8600
12:116575823:T:Aacceptor_loss0.8600
12:116575829:T:Aacceptor_gain0.8400
12:116559494:C:Tdonor_gain0.8300
12:116568041:G:GGdonor_gain0.8200
12:116559610:G:GGdonor_gain0.8100
12:116559404:G:GTdonor_gain0.8000
12:116575839:TAGC:Tacceptor_gain0.7800
12:116576187:T:Aacceptor_gain0.7800
12:116559525:TG:Tdonor_gain0.7700
12:116568040:A:AGdonor_gain0.7700
12:116571800:G:Tdonor_gain0.7700

AlphaMissense

823 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
12:116576096:T:CF52L0.993
12:116576098:C:AF52L0.993
12:116576098:C:GF52L0.993
12:116575990:A:CR16S0.985
12:116575990:A:TR16S0.985
12:116576264:T:CF108L0.984
12:116576266:C:AF108L0.984
12:116576266:C:GF108L0.984
12:116575961:T:CF7L0.982
12:116575963:C:AF7L0.982
12:116575963:C:GF7L0.982
12:116576095:G:CK51N0.982
12:116576095:G:TK51N0.982
12:116575989:G:CR16T0.978
12:116576097:T:CF52S0.978
12:116575966:G:CK8N0.974
12:116575966:G:TK8N0.974
12:116576032:A:CK30N0.973
12:116576032:A:TK30N0.973
12:116576043:T:AI34K0.973
12:116576013:G:CR24P0.972
12:116575989:G:TR16I0.967
12:116576100:T:AL53H0.966
12:116576130:T:CL63P0.965
12:116576210:A:CS90R0.965
12:116576212:C:AS90R0.965
12:116576212:C:GS90R0.965
12:116576297:T:CF119L0.965
12:116576299:C:AF119L0.965
12:116576299:C:GF119L0.965

dbSNP variants (sampled 300 via entrez): RS1000336060 (12:116575037 G>A), RS1000783233 (12:116570481 T>C), RS1000845966 (12:116569230 A>G), RS1000880112 (12:116575337 C>T), RS1000880255 (12:116572735 C>G), RS1001126441 (12:116557769 G>A), RS1001513692 (12:116558059 C>A,T), RS1001611485 (12:116575676 T>A,C), RS1001948422 (12:116576979 A>G), RS1002061746 (12:116564973 T>G), RS1002154336 (12:116571170 C>G), RS1002222283 (12:116570009 G>A,T), RS1002229646 (12:116576041 G>A,T), RS1002398521 (12:116570011 G>A,C), RS1002414506 (12:116558721 C>T)

Disease associations

OMIM: gene MIM:620673 | disease phenotypes:

GenCC curated gene-disease

DiseaseClassificationInheritance
hereditary predisposition to infectionsLimitedAutosomal dominant

Mondo (1): (MONDO:0015979)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

StudyTraitp-value
GCST002875_60Diisocyanate-induced asthma2.000000e-06
GCST006988_116Blond vs. brown/black hair color2.000000e-10

EFO canonical traits (2, from GWAS)

EFO IDTrait name
EFO:0006995response to diisocyanate
EFO:0003924hair color

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
bisphenol Adecreases reaction, increases expression, affects expression, decreases expression4
aristolochic acid Iincreases expression1
ginger extractdecreases expression, increases abundance1
triphenyl phosphateaffects expression1
astaxanthinedecreases reaction, increases expression1
trichostatin Aaffects expression1
beta-lapachoneincreases expression1
sodium arseniteincreases expression1
potassium chromate(VI)increases expression1
di-n-butylphosphoric acidaffects expression1
chromium hexavalent ionincreases expression1
perfluorooctane sulfonic acidincreases expression1
trovafloxacindecreases reaction, increases expression1
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-onedecreases reaction, increases expression1
K 7174increases expression1
3-(4-methylphenylsulfonyl)-2-propenenitriledecreases reaction, increases expression1
abrineincreases expression1
licochalcone Bincreases expression1
jinfukangaffects cotreatment, decreases expression1
Sunitinibincreases expression1
Arsenic Trioxideincreases expression1
Leflunomideincreases expression1
Acetaminophenincreases expression1
Acetylcysteinedecreases reaction, increases expression1
Air Pollutantsincreases abundance, increases expression1
Benzo(a)pyreneaffects methylation, decreases methylation1
Cisplatinaffects cotreatment, decreases expression1
Diquatincreases expression1
Oils, Volatiledecreases expression, increases abundance1
Silverincreases expression1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

CellosaurusNameCategorySex
CVCL_E0H0Ubigene HeLa MAP1LC3B2 KOCancer cell lineFemale

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.